Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603770 · ClinicalTrials.gov registry record · Phase 1
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
A Phase 1 study of Lipid Metabolism Disorder, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02603770 is a Phase 1 study of Lipid Metabolism Disorder that has completed, run by Luye Pharma Group. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02603770, a Phase 1 study of Lipid Metabolism Disorder, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to compare laboratory tests profiles of a botanic drug XueZhiKang (XZK) 300 mg capsules versus a marketed drug Lovastatin 20 mg tablets in healthy male volunteers between 18 and 50 years of age.
Conditions Studied
Interventions
- DRUG Lovastatin
- DRUG XueZhiKang
Study Locations (1)
California
- NRC Research Institute - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603770
The ClinicalTrials.gov registry entry for NCT02603770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipid Metabolism Disorder appearing as the primary indexed condition, and to 2 interventions - of which Lovastatin is the first listed.
NCT02603770 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02603770 about?
NCT02603770 is a clinical study titled "Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers". The objective of this study is to compare laboratory tests profiles of a botanic drug XueZhiKang (XZK) 300 mg capsules versus a marketed drug Lovastatin 20 mg tablets in healthy male volunteers between 18 and 50 years of age.
What is the current status of trial NCT02603770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-11. Estimated completion is 2016-02.
What conditions does trial NCT02603770 study?
This clinical trial studies the following conditions: Lipid Metabolism Disorder.
What interventions are being tested in trial NCT02603770?
The interventions under investigation include: Lovastatin (DRUG), XueZhiKang (DRUG).
Who is sponsoring clinical trial NCT02603770?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603770 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipid Metabolism Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.